NEWS
FACTS ABOUT JD PROTOCOL
After more than 10 years Research by Trials and
Errors, the SBP-4-IMNs, SBP-5-IMNs, and SBP-6-IMNs
are formulated by Dr. John Darmawan, PhD, FACR
With these JD Protocols, Remission under the JD
Protocol, Remission with oral Drugs, and Remission
without Drug can be achieved in 2-4 months, 5.5-7.5
months, and 3.5- 4.5 years in autoimmune diseases
i.e., Rheumatoid Factor Positive Rheumatoid
Arthritis (RF+RA), Lupus Nephritis (LN), and
NSAID-refractory Ankylosing Spondylitis (Nr-AS).
Remission under the JD Protocol in 2-4 months is defined
when:
The ESR is < 25 mm/l hour (men < 15 mm) while the
frequency of intravenous therapy session was tapered off
with the oral therapy consolidating the following status
of the Core Set Endpoints for 3-6 months when the mean:
swollen joint count < 1.0; tender joint count were < 1;
normal CRP; ARA Functional Class < 2; patient global
assessment> 3; visual analog pain scale < 10.
Remission with oral Drugs is defined when:
Normal ESR and CRP; swollen joint count < 1.0; tender
joint count were < 1; ARA Functional Class < 2; patient
global assessment> 3; visual analog pain scale < 10 are
maintained by oral drugs for at least 2 years.
Remission without Drug is defined when:
Oral drugs are tapered off over a period of 1 year and
normal ESR and CRP; swollen joint count < 1.0;
tender joint count were < 1; ARA Functional Class < 2;
patient global assessment> 3; visual analog pain scale <
10 are maintained without drug including Radiological
Remission.
Radiological Remission is defined when:
The mean Rau modified Larsen Index Erosive Joint Count
are zero (healing and termination of the progression of
erosions), and new erosion is prevented.
Safety Precautions of the JD Protocol
Dose-dependent adverse
effects of the components of the combination of
4 intravenous immunosuppressants are avoided by:
minimum daily dosages,
limited to 5Xs weekly administrations, and
before the total maximum cumulative dosages are reached,
intravenous administrations are tapered off,
because Remission has been induced.
The Remission is maintained with oral drugs (Remission
with oral Drugs=RworalDs) with minimum effective dosages
of Mycophenolate Mofetil and Methotrexate.
These minimum oral dosages without adverse effects are
only effective in the patients who have their
Remission induced by the intravenous therapy to normal
ESR in Lupus Nephritis and to normal CRP and ESR in RF+
RA.
Email This Page
Print
This Page
|
|
| |
NEWS & EVENTS
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
16.11.2005
MabThera – a unique approach providing lasting
benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in
difficult-to-treat patients following just two
administrations, two weeks apart
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.09.2005
Roche files first rheumatoid arthritis indication for
MabThera in Europe
MabThera: a medicine used to treat non-Hodgkin's
lymphoma
MabThera delivers significant and sustained relief from
symptoms in patients with difficult-to-treat rheumatoid
arthritis.
›
more
|
|
|
|
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.04.2005
MabThera significantly improves symptoms in patients
with rheumatoid arthritis who inadequately responded to
anti-TNFα therapies
Third large randomised trial to evaluate efficacy and
safety of MabThera in RA
Roche, Genentech and Biogen Idec announced today that
REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its
primary endpoint in the group of patients with the most difficult-to-treat
rheumatoid arthritis (RA).
›
more
|
|
 |
Legal Disclamer
|
Legal Disclaimer
Copyright
©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases.
This Web site was developed in 2005 as a service provided by the
WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases. This Web site provides selected information available
about lupus and arthritis. It is important that public see a
healthcare professional for detailed information about medical
conditions and treatment. This information is not intended to be a
substitute for the advice of a healthcare professional, or a
recommendation for any particular treatment plan. The WHO-ILAR
COPCORD Stage II Education on Treatment of the Autoimmune Diseases
has made and will continue to make efforts to include accurate and
up-to-date information on this Web site.
If you have any
questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
|
|
